Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This compound is a synthetic small molecule belonging to the class of N‑phenylureas. It contains a pyrazolo[4,3-d]pyrimidine core linked via an ethylene bridge to a thiazole ring and further substituted with a trifluoromethylaniline urea moiety. The compound is listed in chemical databases as an experimental pharmaceutical but has no approved medical indications or clinical trial activity reported. Its mechanism of action and biological targets are not described in public sources; it may have been investigated as a kinase inhibitor or for other molecular interactions based on its structure but lacks published pharmacological data.[2][4]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 1-(5-{2-[(1-methyl-1H-pyrazolo[4,3-d]pyrimidin-7-yl)amino]ethyl}-1,3-thiazol-2-yl)-3-[3-(trifluoromethyl)phenyl]urea.